Teladoc, Inc.
Formerly TelaDoc, Inc., a Texas corporation, Cyber Medical Services, Inc.
Teladoc, Inc. is listed today as Teladoc Health, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2020 | $834 M | Private placement after listing | $250 million to $1 billion | equity | SEC | |
| Jul 2017 | $65 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jul 2016 | $80 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Sep 2014 | $50 M | No. 4 | $50 to $250 million | equity | SEC | |
| Aug 2013 | $15 M | Issued in a merger or acquisition | $10 to $50 million | equity | SEC | |
| Aug 2011 | $19 M | No. 3 | $10 to $50 million | equity | SEC | |
| Dec 2010 | $4 M | No. 2 | $2 to $10 million | equity | SEC | |
| Nov 2009 | $9 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Teladoc Health, Inc., its revenue in fiscal 2025 came from these product and service lines: Access Fees $2.09 billion (83%), Other $438.04 million (17%).
Annual report (SEC XBRL) · Dec 2025
Teladoc, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
Revenue range over time, as stated in its notices: revenue between $5 million and $25 million in 2013; revenue between $25 million and $100 million in 2014; revenue between $25 million and $100 million in 2016; revenue of over $100 million in 2017.
SEC Form D (revenue range) · Jul 2017
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jul 2020
Products and services#
No products or services of Teladoc, Inc. are on record.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| CHP III LP | Fund or asset manager | not stated | not stated | Held Series C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| CHP III Management, L.L.C. | Fund or asset manager | not stated | not stated | Held Series C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| HLM Venture Associates II, LLC | Venture capital | not stated | not stated | Held Series C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| HLM Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Jason N. Gorevic | Person | not stated | not stated | Held Series A-1, C-1 and F preferred stock, director (Form 3, 2015) | SEC Form 3 |
| KPCB DGF Associates, LLC | Other | not stated | not stated | Held Series D and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| KPCB Digital Growth Founders Fund, LLC | Fund or asset manager | not stated | not stated | Held Series D and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| KPCB Digital Growth Fund, LLC | Fund or asset manager | not stated | not stated | Held Series D and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Mark Hirschhorn | Person | not stated | not stated | Held Series A-1, C-1 and F preferred stock (Form 3, 2015) | SEC Form 3 |
| Michael H. King | Person | not stated | not stated | Held Series A-1, C-1 and F preferred stock (Form 3, 2015) | SEC Form 3 |
| Trident Capital Fund VI LP | Fund or asset manager | not stated | not stated | Held Series B, C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Trident Capital Fund VI Principals Fund LLC | Fund or asset manager | not stated | not stated | Held Series B, C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Trident Capital Management-VI, L.L.C. | Fund or asset manager | not stated | not stated | Held Series B, C-1, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 40 investors.
Largest shareholders today
Institutions holding Teladoc Health, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$109 M10.28%
- Vanguard Portfolio Management LLC$83 M7.83%
- American Century Companies Inc$55 M5.22%
- Dimensional Fund Advisors LP$53 M4.99%
- Voss Capital, LP$51 M4.84%
- Renaissance Technologies LLC$46 M4.39%
- Vanguard Capital Management LLC$46 M4.38%
- Point72 Asset Management, L.P.$46 M4.36%
- State Street Corp$29 M2.71%
- Geode Capital Management, LLC$27 M2.55%
- Allianz Asset Management GmbH$25 M2.38%
- Charles Schwab Investment Management Inc$20 M1.85%
- Goldman Sachs Group Inc$18 M1.73%
- Quantinno Capital Management LP$16 M1.53%
- Acadian Asset Management LLC$16 M1.51%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam C. Vandervoort | Executive officer | Jul 2020 |
| Andrew M. Turitz | Executive officer | Jul 2020 |
| Christopher F. Caridi | Executive officer | Jul 2020 |
| David W. Sides | Executive officer | Jul 2020 |
| Jason N. Gorevic | Executive officer | Jul 2020 |
| Lewis C. Levy | Executive officer | Jul 2020 |
| Mala C. Murthy | Executive officer | Jul 2020 |
| Michelle C. Bucaria | Executive officer | Jul 2020 |
| Stephanie F. Verstraete | Executive officer | Jul 2020 |
| Gabriel R. Cappucci | Executive officer | Jul 2017 |
| Jason Gorevic | Executive officer | Jul 2017 |
| Mark Hirschhorn | Executive officer | Jul 2017 |
| Michael King | Executive officer | Jul 2017 |
| Daniel B. Trencher | Executive officer | Sep 2014 |
| Henry B. DePhillips | Executive officer | Sep 2014 |
| Jeff Nadler | Executive officer | Sep 2014 |
| Kevin Williamson | Executive officer | Sep 2014 |
| Mark B. Hirschhorn | Executive officer | Sep 2014 |
| Mike B. King | Executive officer | Sep 2014 |
| Thomas B. Seaman | Executive officer | Sep 2014 |
| Dan Trencher | Executive officer | Sep 2013 |
| Henry DePhillips | Executive officer | Sep 2013 |
| Mike King | Executive officer | Sep 2013 |
| Paul Squire | Executive officer | Sep 2013 |
| Bill Giles | Executive officer | Sep 2011 |
| Richard Boxer | Executive officer | Sep 2011 |
| Catherine A. Jacobson | Director | Jul 2020 |
| David B. Snow | Director | Jul 2020 |
| David L. Shedlarz | Director | Jul 2020 |
| Helen H. Darling | Director | Jul 2020 |
| Jason N. Gorevic | Director | Jul 2020 |
| Kenneth H. Paulus | Director | Jul 2020 |
| Mark D. Smith | Director | Jul 2020 |
| Michael M. Goldstein | Director | Jul 2020 |
| Tom G. Mckinley | Director | Jul 2020 |
| William H. Frist | Director | Jul 2020 |
| Arneek G. Multani | Director | Jul 2017 |
| David B. Snow, Jr. | Director | Jul 2017 |
| David H. Shedlarz | Director | Jul 2017 |
| Helen B. Darling | Director | Jul 2017 |
About
American healthcare company.
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.